Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...
The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a comprehensive analysis of current and future ...
Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW ...
Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers ...
Humanetics Corporation (Humanetics) announced today the launch of a new investigator-initiated clinical trial (IIT) of BIO 300 Oral Suspension (BIO 300), led by Dr. Narek Shaverdian, Director of ...
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.
Starting treatment of study participants in the RASolute 303 trial represents an important milestone for our daraxonrasib program and for patients with metastatic pancreatic cancer, a disease with ...
Safety and QoL considerations are reshaping sequencing, including avoidance of immunotherapy in certain drivers and adoption ...
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...
MAIA Biotechnology, Inc. announced that eight patients with non-small cell lung cancer in an ongoing phase 2 THIO-101 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results